References
Bernard GR, Vincent JL, Laterrre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Eli EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
Vincent J-L, Bernard G, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266–2277
Mackenzie AF (2005) Activated protein C: do more survive? Intensive Care Med 31:1624–1626
Macias WL (2006) Activated protein C: do more survive? Intensive Care Med 32:605–631
Kothari VM, Karnad CR, Bichile LS (2006) Tropical infections in ICU J Assoc Physicians India 54:291–298
Krishnan A, Karnad D (2003) Severe falciparum malaria: an important cause of multiple organ failure in Indian intensive care units. Crit Care Med 31:2278–2284
Kuriakose CK, Eapen, Paul R (1997) Leptospirosis in Kolenchery, Kerala, India: epidemiology, prevalent local serogroups and servoars and a new serovar. Eur J Epidemiol 13:691–697
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kapadia, F., Shirwadkar, C. Drotrecogin alfa in tropical infections and refractory multi-organ failure. Intensive Care Med 32, 1281–1282 (2006). https://doi.org/10.1007/s00134-006-0230-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-006-0230-6